Tempest Therapeutics, Inc. (TPST) stock
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.00 (-0.29%)
Close on Nov 13, 2026Market cap $5.65MP/E –Yield –
Tempest Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Tempest Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.68M, down 88.3% year over year. For fiscal 2025 it was $12.61M, down 55.7% from the year before. Over ten years it grew -3.7% a year on average. The highest annual figure on record is $28.48M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.61M | -55.7% |
| FY2024 | Dec 31, 2024 | $28.48M | +62.7% |
| FY2023 | Dec 31, 2023 | $17.50M | -22.3% |
| FY2022 | Dec 31, 2022 | $22.53M | +31.2% |
| FY2021 | Dec 31, 2021 | $17.17M | +19.3% |
| FY2020 | Dec 31, 2020 | $14.39M | -48.3% |
| FY2019 | Dec 31, 2019 | $27.84M | +93.0% |
| FY2018 | Dec 31, 2018 | $14.43M | -0.7% |
| FY2017 | Dec 31, 2017 | $14.53M | -32.9% |
| FY2016 | Dec 31, 2016 | $21.64M | +17.4% |
| FY2015 | Dec 31, 2015 | $18.43M | -15.4% |
| FY2014 | Dec 31, 2014 | $21.78M | +37.9% |
| FY2013 | Dec 31, 2013 | $15.80M | +149.9% |
| FY2012 | Dec 31, 2012 | $6.32M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $207.00K | -63.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.82M | -53.0% |
| Q1 FY2026 | Mar 31, 2026 | $114.00K | -98.5% |
| Q4 FY2025 | Dec 31, 2025 | $539.00K | -95.0% |
| Q3 FY2025 | Sep 30, 2025 | $570.00K | -92.5% |
| Q2 FY2025 | Jun 30, 2025 | $3.87M | -33.7% |
| Q1 FY2025 | Mar 31, 2025 | $7.63M | +75.7% |
| Q4 FY2024 | Dec 31, 2024 | $10.74M | +156.8% |
| Q3 FY2024 | Sep 30, 2024 | $7.56M | +79.0% |
| Q2 FY2024 | Jun 30, 2024 | $5.84M | +32.2% |
| Q1 FY2024 | Mar 31, 2024 | $4.34M | -7.2% |
| Q4 FY2023 | Dec 31, 2023 | $4.18M | -27.8% |
| Q3 FY2023 | Sep 30, 2023 | $4.22M | -29.3% |
| Q2 FY2023 | Jun 30, 2023 | $4.42M | -21.9% |
| Q1 FY2023 | Mar 31, 2023 | $4.68M | -8.4% |
| Q4 FY2022 | Dec 31, 2022 | $5.79M | +22.9% |
| Q3 FY2022 | Sep 30, 2022 | $5.97M | +29.0% |
| Q2 FY2022 | Jun 30, 2022 | $5.65M | +33.6% |
| Q1 FY2022 | Mar 31, 2022 | $5.11M | +42.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.72M | +57.3% |
| Q3 FY2021 | Sep 30, 2021 | $4.63M | +8.4% |
| Q2 FY2021 | Jun 30, 2021 | $4.23M | +3.3% |
| Q1 FY2021 | Mar 31, 2021 | $3.59M | -52.4% |
| Q4 FY2020 | Dec 31, 2020 | $3.00M | -64.1% |
| Q3 FY2020 | Sep 30, 2020 | $4.27M | -41.6% |
| Q2 FY2020 | Jun 30, 2020 | $4.09M | -31.5% |
| Q1 FY2020 | Mar 31, 2020 | $7.54M | +21.5% |
| Q4 FY2019 | Dec 31, 2019 | $8.35M | +82.1% |
| Q3 FY2019 | Sep 30, 2019 | $7.31M | +88.8% |
| Q2 FY2019 | Jun 30, 2019 | $5.98M | +86.9% |
| Q1 FY2019 | Mar 31, 2019 | $6.20M | +124.1% |
| Q4 FY2018 | Dec 31, 2018 | $4.59M | +28.8% |
| Q3 FY2018 | Sep 30, 2018 | $3.87M | -3.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.20M | -36.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.77M | -52.0% |
| Q4 FY2017 | Dec 31, 2017 | $3.56M | -24.4% |
| Q3 FY2017 | Sep 30, 2017 | $4.02M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.76M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.71M | – |
See a number that looks wrong?